Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer

Loh, Joshua P.; Low, Jia Li; Sachdeva, Manavi; Wong, Raymond Chung Wen; Huang, Yiqing; Chia, Puey Ling; Soo, Ross A.

doi:10.1080/14737140.2023.2245140

Expert Review of Anticancer Therapy

2023

DOI: 10.1080/14737140.2023.2245140

|View full text |Cite

Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer

Joshua P. Loh

Jia Li Low

Manavi Sachdeva

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The role of chemoradiotherapy and immunotherapy in stage III NSCLC

Orosz,

Kovács

2024

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Locally advanced non-small lung cancer encompasses a diverse range of tumors. In the last few years, the treatment of stage III unresectable non-small lung cancer has evolved significantly. The PACIFIC trial opened a new therapeutic era in the treatment of locally advanced NSCLC, establishing durvalumab consolidation therapy as the new standard of care worldwide. A careful evaluation of this type of lung cancer and a discussion of the management of these patients within a multidisciplinary team represents a crucial step in defining the best treatment strategy for each patient. For unresectable stage III NSCLC, definitive concurrent chemoradiotherapy (CCRT) was historically recommended as a treatment with a 5-year survival rate ranging from 20% to 30%. The PACIFIC study conducted in 2017 compared the use of chemoradiotherapy and maintenance therapy with the anti-PD-L1 monoclonal antibody durvalumab to a placebo in patients with locally advanced NSCLC who had not experienced disease progression. The study was prospective, randomized, and phase III. The administration of this medication in patients with locally advanced non-small cell lung cancer (NSCLC) has demonstrated a notable improvement in overall survival. Multiple clinical trials are currently exploring various immune checkpoint inhibition regimens to enhance the treatment efficacy in patients with stage III cancer. Our goal is to offer an up-to-date summary of the planned clinical trials for treatment options, focusing on the significant obstacles and prospects in the post-PACIFIC era.

show abstract

The role of chemoradiotherapy and immunotherapy in stage III NSCLC

Orosz,

Kovács

2024

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer

Cited by 1 publication

References 123 publications

The role of chemoradiotherapy and immunotherapy in stage III NSCLC

The role of chemoradiotherapy and immunotherapy in stage III NSCLC

Contact Info

Product

Resources

About